. 2022 Mar 24;23(7):3559. doi: 10.3390/ijms23073559
© 2022 by the authors.
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Figure 2.
Tumor infiltrating lymphocytes (TILs) therapy.